Natixis Advisors L.P. Has $12.06 Million Stock Holdings in Veeva Systems Inc. (NYSE:VEEV)

Natixis Advisors L.P. reduced its position in Veeva Systems Inc. (NYSE:VEEV - Free Report) by 77.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,624 shares of the technology company's stock after selling 218,676 shares during the period. Natixis Advisors L.P.'s holdings in Veeva Systems were worth $12,056,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. OFI Invest Asset Management acquired a new stake in shares of Veeva Systems in the third quarter valued at approximately $25,000. Operose Advisors LLC acquired a new stake in Veeva Systems during the 3rd quarter valued at $29,000. Parkside Financial Bank & Trust increased its position in Veeva Systems by 81.9% during the third quarter. Parkside Financial Bank & Trust now owns 171 shares of the technology company's stock worth $35,000 after buying an additional 77 shares in the last quarter. Atticus Wealth Management LLC increased its position in Veeva Systems by 500.0% during the third quarter. Atticus Wealth Management LLC now owns 180 shares of the technology company's stock worth $37,000 after buying an additional 150 shares in the last quarter. Finally, Nkcfo LLC raised its holdings in shares of Veeva Systems by 54.7% in the third quarter. Nkcfo LLC now owns 232 shares of the technology company's stock worth $47,000 after acquiring an additional 82 shares during the last quarter. 88.20% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

VEEV has been the subject of a number of recent research reports. Royal Bank of Canada reiterated an "outperform" rating and set a $250.00 price objective on shares of Veeva Systems in a research report on Wednesday, March 27th. Truist Financial boosted their price objective on shares of Veeva Systems from $187.00 to $203.00 and gave the company a "hold" rating in a research report on Friday, March 1st. Stifel Nicolaus lifted their target price on shares of Veeva Systems from $205.00 to $250.00 and gave the stock a "buy" rating in a research note on Friday, March 1st. Piper Sandler boosted their price target on Veeva Systems from $220.00 to $245.00 and gave the company an "overweight" rating in a report on Friday, March 1st. Finally, JPMorgan Chase & Co. raised their price objective on Veeva Systems from $183.00 to $222.00 and gave the stock a "neutral" rating in a report on Wednesday, March 13th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Veeva Systems has a consensus rating of "Moderate Buy" and a consensus price target of $234.90.

Veeva Systems Stock Performance

VEEV traded down $3.57 on Wednesday, reaching $201.74. 621,387 shares of the company's stock were exchanged, compared to its average volume of 943,042. The company has a market cap of $32.54 billion, a price-to-earnings ratio of 62.65, a PEG ratio of 2.05 and a beta of 0.76. Veeva Systems Inc. has a twelve month low of $160.21 and a twelve month high of $236.90. The company's 50 day moving average is $216.61 and its 200-day moving average is $202.11.

Veeva Systems (NYSE:VEEV - Get Free Report) last issued its earnings results on Thursday, February 29th. The technology company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.81 by $0.11. Veeva Systems had a net margin of 22.24% and a return on equity of 11.26%. The business had revenue of $630.62 million for the quarter, compared to the consensus estimate of $620.75 million. Sell-side analysts forecast that Veeva Systems Inc. will post 4.11 EPS for the current year.

Insiders Place Their Bets

In other Veeva Systems news, Director Timothy S. Cabral sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $226.04, for a total value of $3,390,600.00. Following the completion of the transaction, the director now owns 23,391 shares in the company, valued at approximately $5,287,301.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, EVP Alan Mateo sold 3,391 shares of Veeva Systems stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $200.86, for a total transaction of $681,116.26. Following the sale, the executive vice president now directly owns 21,983 shares of the company's stock, valued at $4,415,505.38. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Timothy S. Cabral sold 15,000 shares of the stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $226.04, for a total value of $3,390,600.00. Following the completion of the transaction, the director now directly owns 23,391 shares of the company's stock, valued at approximately $5,287,301.64. The disclosure for this sale can be found here. Insiders have sold a total of 21,989 shares of company stock worth $4,818,013 over the last quarter. 10.50% of the stock is owned by corporate insiders.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.